Dr. Bonita has served on Ikena’s board since March 2016 and is a member of OrbiMed Advisors LLC. Current and former board roles include Acutus Medical Inc., Prelude Therapeutics, Inc., Repare, Third Harmonic Bio, Inc., IMARA, Inc. and Tricida, Inc.
Kristin Yarema, Ph.D. was chief executive officer and director of Poseida Therapeutics until its acquisition by Roche in January 2025, then stayed to guide the transition. She was Poseida's president of cell therapy from April to December 2023.
Dr. Stampacchia has served on Ikena’s board since December 2020 and is founder and managing director at Omega Funds LLC. Previous board roles include Kronos Bio, Inc., Median Technologies, Inc., Nuvation Bio, Inc. and Replimune Group, Inc.
ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients who have immunological, autoimmune and inflammatory diseases.